Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 35

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
068 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld246,153 — (1,299)— — (1,299)Net earnings (loss)— — — — (11,827)(11,827)Unrealized gain on marketable securities, net of tax— — — 30 — 30 Balance, March 31, 202555,989,248 $56 $486,209 $(159)$544,599 $1,030,705 

Common StockAdditional Paid-in CapitalAccumulated OtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders’EquitySharesAmountBalance, December 31, 202354,723,356 $55 $439,493 $(593)$482,561 $921,516 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 5,897 — — 5,897 Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld241,960 — 1,570 — — 1,570 Net earnings— — — — 124 124 Unrealized gain on marketable securities, net of tax— — — 59 — 59 Balance, March 31, 202454,965,316 $55 $446,960 $(534)$482,685 $929,166 

See accompanying notes.

6

 Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)Three Months Ended March 31,20252024(unaudited)Cash flows from operating activitiesNet earnings (loss)$(11,827)$124 Adjustments to reconcile net earnings (loss) to net cash provided by operating activities:Depreciation and amortization20,383 20,749 Amortization of premium/discount on marketable securities(1,074)1,894 Change in fair value of contingent consideration7,660 (1,095)Share-based compensation expense8,068 5,897 Deferred income tax benefit(3,990)(5,482)Inventory valuation write-down547 730 Payment of contingent consideration(4,900)— Other noncash adjustments, net1,826 1